Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
Tài liệu tham khảo
Ntalos, 2020, Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke. The Global COVID-19 Stroke Registry, Stroke, 51, e254
Merkler, 2020, Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza, JAMA Neurol., 77, 1, 10.1001/jamaneurol.2020.2730
Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5
Beyrouti, 2020, Characteristics of ischaemic stroke associated with COVID-19, J. Neurol. Neurosurg. Psychiatry, 91, 889, 10.1136/jnnp-2020-323586
Oxley, 2020, Large-vessel stroke as a presenting feature of COVID-19 in the young, N. Engl. J. Med., 382, 10.1056/NEJMc2009787
Conklin, 2021, Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19, J. Neurol. Sci., 421, 117308, 10.1016/j.jns.2021.117308
de Jongh, 2002, Early statin therapy restores endothelial function in children with familial hypercholesterolemia, J. Am. Coll. Cardiol., 40, 2117, 10.1016/S0735-1097(02)02593-7
Vuorio, 2020, Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia, J. Clin. Lipidol., 14, 617, 10.1016/j.jacl.2020.06.006
Schlager, 2013, Familial hypercholesterolemia affects microvascular autoregulation in children, Metabolism, 62, 820, 10.1016/j.metabol.2012.12.013
Kaste, 1988, Risk of brain infarction in familial hypercholesterolemia, Stroke, 19, 1097, 10.1161/01.STR.19.9.1097
Soljanlahti, 2005, Familial hypercholesterolemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis, Stroke, 36, 1572, 10.1161/01.STR.0000169920.64180.fa
Undas, 2014, Anticoagulant effects of statins and their clinical implications, Thromb. Haemost., 111, 392, 10.1160/TH13-08-0720
Mehra, 2020, Cardiovascular disease, drug therapy, and mortality in COVID-19, N. Engl. J. Med., 382, 10.1056/NEJMc2021225
Stock, 2019, First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated, Atherosclerosis, 290, 138, 10.1016/j.atherosclerosis.2019.09.015
Pang, 2021, Gaps in the care of familial hypercholesterolaemia in Australia: first report from the National Registry, Heart Lung Circ., 2021, 372, 10.1016/j.hlc.2020.07.012
Yaman, 2021, Awareness, treatment rates, and compliance to treatment in patients with serum LDL cholesterol higher than 250 mg/dL, and possible, probable, or definite familial hypercholesterolemia, Postgrad. Med., 133, 146, 10.1080/00325481.2020.1805212
Vuorio, 2020, Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities, J. Intern. Med., 287, 2, 10.1111/joim.12981
Moriarty, 2020, Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis, Curr. Atheroscler. Rep., 22, 48, 10.1007/s11883-020-00867-3
Tsimikas, 2020, Statins and increases in Lp(a): an inconvenient truth that needs attention, Eur. Heart J., 41, 192, 10.1093/eurheartj/ehz776
Vuorio, 2017, Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a), Eur. Heart J., 38, 3555, 10.1093/eurheartj/ehx546
Vuorio, 2021, Statins as adjuvant therapy for COVID-19 to calm the stormy immunothrombosis and beyond, Front. Pharmacol., 11, 579548, 10.3389/fphar.2020.579548
Kow, 2020, Meta-analysis of effect of statins in patients with COVID-19, Am. J. Cardiol., 134, 153, 10.1016/j.amjcard.2020.08.004